MolecularMD Offers Testing Services for Determining LKB1 Mutation and Expression Status
4/9/2013 12:18:31 PM
More...
|
MolecularMD Announces Launch of Next Generation Sequencing Services for Oncology Drug Development
4/4/2013 9:25:56 AM
More...
|
MolecularMD Obtains Exclusive License to LKB1 Uses in Non-Small Cell Lung Cancer
1/28/2013 8:47:01 AM
More...
|
MolecularMD and Ventana Medical Systems, Inc. (VMSI) Reach Collaborative Research Agreement: Limits of Detection and Sensitivity for PTEN Gene Using In-Situ Hybridization and Immunohistochemistry Methods
12/6/2012 10:03:55 AM
More...
|
MolecularMD Announces Next Generation Sequencing Presentation at Upcoming American Society of Hematology Annual Meeting
12/6/2012 10:02:55 AM
More...
|
MolecularMD Announces Three Presentations Highlighting Non-Invasive Biomarker Detection and NGS Validation at Upcoming Scientific Conferences
10/24/2012 8:47:08 AM
More...
|
MolecularMD and Ariad Pharmaceuticals, Inc. (ARIA) Announce Voluntary Withdrawal of MolecularMD's Premarket Approval Application for BCR-ABL T315I Mutation Test
9/18/2012 8:37:44 AM
More...
|
MolecularMD Submits Premarketing Approval Application to the FDA for Its BCR-ABL T315I Mutation Test, a Companion Diagnostic to Ponatinib, an Investigational BCR-ABL Inhibitor
7/31/2012 9:13:48 AM
More...
|
MolecularMD Closes $6 Million Series B Financing and Announces Ensuing Growth Initiatives
4/2/2012 7:20:19 AM
More...
|
MolecularMD Announces Issuance of Patent Covering Methods for Therapeutic Resistance Monitoring in Lung Cancer Patients
12/9/2011 8:59:50 AM
More...
|
|